Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith, Kenneth J., Mary Patricia Nowalk, Mahlon Raymund, and Richard K. Zimmerman. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. http://www.ncbi.nlm.nih.gov/pubmed/23806240

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith, Kenneth J., Mary Patricia Nowalk, Mahlon Raymund, and Richard K. Zimmerman
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Staff vaccination in nursing homes reduces mortality rates of residents
    Mortality rates in nursing home residents were 42% lower in facilities with higher staff vaccination coverage compared with control facilities.  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Value of polio eradication
    Eradication of polio is estimated to produce savings to governments of $1.5 billion per year.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.